Mebutamate
Dormate (mebutamate) is a small molecule pharmaceutical. Mebutamate was first approved as Dormate on 1982-01-01.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Mebutamate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| DORMATE | Medpointe Pharm Hlc | N-017374 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| 2xl mega roll sanitizing wipes 2300 count megaroll | OTC monograph not final | 2022-11-29 |
| 2xl mega rolls sanitizing wipes | C200263 | 2024-12-06 |
| bain de soleil | OTC monograph final | 2023-09-08 |
| cablivi | Biologic Licensing Application | 2024-11-04 |
| cellbn mega plus | unapproved drug other | 2017-05-29 |
| dr andrew weils for origins | C200263 | 2023-09-11 |
| dr weils mega-defense advanced daily uv defender broad spectrum spf 45 | OTC monograph not final | 2021-07-14 |
| dr. andrew weil for origins | C200263 | 2024-12-25 |
| jba verestor mega fiber caffe latte | unapproved drug other | 2024-11-11 |
| jba verestor mega fiber powder | unapproved drug other | 2024-11-11 |
Show 31 more
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
282 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obesity | D009765 | EFO_0001073 | E66.9 | — | 1 | — | 1 | 7 | 9 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | 1 | 1 | — | 1 | 4 | 7 |
| Insulin resistance | D007333 | EFO_0002614 | E88.819 | — | — | 1 | 1 | 3 | 5 |
| Critical illness | D016638 | — | — | — | — | — | 1 | 3 | 4 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | — | — | 2 | 1 | 1 | 4 |
| Resistance training | D055070 | — | — | — | — | — | 1 | 3 | 4 |
| Myofascial pain syndromes | D009209 | EFO_1001054 | — | — | — | — | 1 | 3 | 4 |
| Fibromyalgia | D005356 | EFO_0005687 | M79.1 | — | — | — | 1 | 3 | 4 |
| Lung diseases | D008171 | EFO_0003818 | J98.4 | — | — | 1 | 1 | 1 | 3 |
| Obstructive lung diseases | D008173 | — | — | — | — | 2 | 1 | — | 3 |
Show 12 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 1 | 3 | 1 | — | 2 | 6 |
| Leukemia | D007938 | — | C95 | — | 2 | 3 | — | — | 4 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | — | 2 | 3 | — | — | 4 |
| Lymphoid leukemia | D007945 | — | C91 | — | 2 | 3 | — | — | 4 |
| Prostatic neoplasms | D011471 | — | C61 | 1 | 3 | 2 | — | — | 4 |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | — | — | 1 | — | 3 | 4 |
| Attention deficit disorder with hyperactivity | D001289 | EFO_0003888 | F90 | — | — | 1 | — | 3 | 4 |
| Precursor t-cell lymphoblastic leukemia-lymphoma | D054218 | — | — | — | 1 | 2 | — | — | 3 |
| Lymphoma | D008223 | — | C85.9 | — | — | 2 | — | 1 | 3 |
| Dyslipidemias | D050171 | — | — | — | — | 1 | — | 2 | 3 |
Show 17 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Syndrome | D013577 | — | — | — | 2 | — | — | 7 | 9 |
| Sleep initiation and maintenance disorders | D007319 | — | F51.01 | — | 1 | — | — | 4 | 5 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | — | — | 2 | 3 |
| Carcinoma | D002277 | — | C80.0 | 1 | 2 | — | — | 1 | 3 |
| Anemia | D000740 | EFO_0004272 | D64.9 | 1 | 1 | — | — | 1 | 3 |
| Cognitive dysfunction | D060825 | — | G31.84 | — | 1 | — | — | 2 | 3 |
| Esophageal neoplasms | D004938 | — | C15 | — | 2 | — | — | — | 2 |
| Hematologic neoplasms | D019337 | — | — | 1 | 1 | — | — | 1 | 2 |
| Memory | D008568 | — | — | — | 1 | — | — | 1 | 2 |
| Colorectal neoplasms | D015179 | — | — | — | 1 | — | — | — | 1 |
Show 22 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | 7 | 8 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 1 | — | — | — | 4 | 5 |
| Depression | D003863 | — | F33.9 | 1 | — | — | — | 4 | 5 |
| Glioma | D005910 | EFO_0000520 | — | 1 | — | — | — | 4 | 5 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | 1 | — | — | — | 4 | 5 |
| Transcranial magnetic stimulation | D050781 | — | — | 1 | — | — | — | 1 | 2 |
| Glioblastoma | D005909 | EFO_0000515 | — | 1 | — | — | — | 1 | 2 |
| Fanconi anemia | D005199 | Orphanet_84 | D61.03 | 1 | — | — | — | — | 1 |
| Fanconi syndrome | D005198 | — | — | 1 | — | — | — | — | 1 |
| Neuronal plasticity | D009473 | — | — | 1 | — | — | — | — | 1 |
Show 3 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Exercise | D015444 | EFO_0000483 | — | — | — | — | — | 8 | 8 |
| Dental caries | D003731 | EFO_0003819 | K02 | — | — | — | — | 8 | 8 |
| Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | — | — | — | — | 7 | 7 |
| Covid-19 | D000086382 | — | U07.1 | — | — | — | — | 6 | 6 |
| Overweight | D050177 | — | E66.3 | — | — | — | — | 5 | 5 |
| Postoperative pain | D010149 | — | G89.18 | — | — | — | — | 5 | 5 |
| Psychomotor agitation | D011595 | — | — | — | — | — | — | 4 | 4 |
| Aging | D000375 | GO_0007568 | R41.81 | — | — | — | — | 4 | 4 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | — | — | — | 4 | 4 |
| Mental disorders | D001523 | EFO_0000677 | F91.9 | — | — | — | — | 4 | 4 |
Show 232 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Mebutamate |
| INN | mebutamate |
| Description | Mebutamate (Capla, Dormate) is an anxiolytic and sedative drug with antihypertensive effects of the carbamate class. It has effects comparable to those of barbiturates such as secobarbital, but is only around 1/3 the potency of secobarbital as a sedative. Side effects include dizziness and headaches.
|
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCC(C)C(C)(COC(N)=O)COC(N)=O |
Identifiers
| PDB | — |
| CAS-ID | 64-55-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1200922 |
| ChEBI ID | — |
| PubChem CID | 6151 |
| DrugBank | — |
| UNII ID | 5H8F175RER (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 31,592 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
6,990 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use